Published on 3 Sep 2022 on Zacks via Yahoo Finance
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose
Pliant Therapeutics PLRX received a positive safety review of the ongoing INTGERIS-IPF phase IIa study evaluating PLN-74809 at 320 mg for the treatment of idiopathic pulmonary fibrosis (IPF) from the independent Data Safety Monitoring Board (DSMB).
The DSMB meeting was held per regular schedule after the completion of the enrollment of the study in its 320 mg cohort.
The DSMB examined the safety data from all the subjects enrolled in the study and recommended that the company continue with the study without any modification. The positive review further confirms PLN-74809's safety profile to date.